Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$482.27 USD

482.27
956,306

-6.51 (-1.33%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats

by Zacks Equity Research

OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.

Here's Why You Should Add McKesson (MCK) to Your Portfolio

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.

Reasons to Add Inari Medical (NARI) Stock to Your Portfolio

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on adoption of products is a concern.

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Accuray's (ARAY) Tomo C Radiation System Gets Approval in China

by Zacks Equity Research

Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.

Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery

by Zacks Equity Research

Veradigm's (MDRX) new phase of strategic investment is likely to drive innovation and close the evidence gap in behavioral health.

Reasons to Add Stryker (SYK) Stock to Your Portfolio Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the stock.

Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans

by Zacks Equity Research

Accuray's (ARAY) latest offering is likely to improve radiation treatment.

Cardinal Health (CAH) Launches Next-Gen Enteral Feeding Pump

by Zacks Equity Research

Cardinal Health's (CAH) Kangaroo OMNI enteral feeding pump, with new portable design and effectiveness in terms of personalized care, is likely to improve the quality of life for patients.

Mark Vickery headshot

Manufacturing Data Improves, Bond Yields Stay Elevated

by Mark Vickery

We got some slightly better September Manufacturing numbers than expected from the final S&P PMI and ISM reports.

Why McKesson (MCK) is a Top Value Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Shopify, Caterpillar, Amgen in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes

by Zacks Equity Research

Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve.

Sumit Singh headshot

4 Stocks That Stand Out on Attractive Interest Coverage Ratio

by Sumit Singh

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOD, SFM, MOH and MCK are sound enough to meet financial obligations.

Here's Why You Should Retain Ecolab (ECL) Stock for Now

by Zacks Equity Research

Ecolab's (ECL) strength in its business raises optimism about the stock.

Zacks.com featured highlights include Applied Materials, PulteGroup, Arcos Dorados Holdings, McKesson, and NetEase

by Zacks Equity Research

Applied Materials, PulteGroup, Arcos Dorados Holdings, McKesson, and NetEase are part of the Zacks Screen of the Week article.

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

DexCom (DXCM) Partners With RxFood for Automated Dietary Monitoring

by Zacks Equity Research

DexCom's (DXCM) CGM systems will make dietary assessment through AI-enabled RxFood app, which automatically interprets food images for calorie count in Canada.

Sweta Killa headshot

Dive Into Dividends: Top 5 Bargain Growth Stocks to Buy

by Sweta Killa

Applied Materials (AMAT), PulteGroup (PHM), Arcos Dorados (ARCO), McKesson (MCK) and NetEase (NTES) could be compelling picks for investors in the current scenario.

Here's Why You Should Retain Inspire Medical (INSP) Stock Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

NextGen (NXGN) Extends Agreement to Boost Athletico's Footprint

by Zacks Equity Research

NextGen's (NXGN) latest extended agreement is likely to reflect its solutions' potential to aid healthcare organizations at all stages of growth.

Reasons to Retain Patterson Companies (PDCO) in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

HealthEquity (HQY) to Add Conduent's HSA Accounts in 2024

by Zacks Equity Research

HealthEquity (HQY) is set to receive the Conduent's HSA portfolio as a part of an agreement signed by the companies earlier this month. The deal is likely to boost HQY's business in 2024 and beyond.

QuidelOrtho's (QDEL) Rapid Antigen Test Gets CLIA Waiver

by Zacks Equity Research

QuidelOrtho's (QDEL) receipt of the FDA's CLIA waiver is expected to widen access to the rapid antigen test in any point-of-care setting equipped with Sofia 2 instruments.